Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Blood. 2009 Jun 4;113(23):5743-6. doi: 10.1182/blood-2009-01-201988. Epub 2009 Apr 3.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma.

Author information

  • 1Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, USA.

Abstract

Previous studies demonstrated that vaccination-induced tumor-specific immune response is associated with superior clinical outcome in patients with follicular lymphoma. Here, we investigated whether this positive correlation extends to overall survival (OS). We analyzed 91 untreated patients who received CVP chemotherapy (cyclophosphamide, vincristine, and prednisone) followed by idiotype vaccination. Idiotype proteins were produced either by the hybridoma method or by expression of recombinant idiotype-encoding sequences in mammalian or plant-based expression systems. We found that achieving a complete response/complete response unconfirmed (CR/CRu) to CVP and making an anti-idiotype antibody are 2 independent factors that each correlated with longer OS at 10 years (89% vs 68% with or without a CR/CRu, P = .024; 90% vs 69% with or without tumor-specific antibody production; P = .027). In the subset of patients who received hybridoma-generated vaccines, we found that anti-idiotype production was even more highly associated with superior OS (P < .002); this was the case even in patients with a partial response (PR) to CVP (P < .001).

PMID:
19346494
[PubMed - indexed for MEDLINE]
PMCID:
PMC2700314
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk